FDA Requires New Warning for Testosterone Products
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Topics
NDA for Empagliflozin Resubmitted to FDA
Boehringer Ingelheim and Eli Lilly and Company announced the resubmission of the empagliflozin NDA to the FDA for the treatment of adults with type 2 diabetes.
Adrenal Incidentaloma Management May Need Improvement
Many patients with adrenal incidentaloma may not receive the necessary care for their condition.
Bone Mineral Density Increased With Romosozumab
Romosozumab significantly increased bone mineral density and bone content in postmenopausal women.
Parathyroid Hormone Predicts Vitamin D’s Effect on Glucose Metabolism
Levels of parathyroid hormone (PTH) should be considered when evaluating the effect of vitamin D status on glucose metabolism.
Lenvatinib Promising for Radioiodine-Resistant Thyroid Cancer
Lenvatinib, a new TKI inhibitor, delays disease progression and shows promising clinical efficacy against differentiated radioiodine-resistant thyroid cancer.
Reviewing Effects of BPA
Primarily used in food and drink packaging, ingestion of bisphenol A has been linked to obesity, diabetes and reproductive disorders.
Long-Acting Release Signifor Effective in Acromegaly Trial
Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.
FDA Approves Tanzeum for Type 2 Diabetes
The FDA has approved Tanzeum (albiglutide) subcutaneous injection for type 2 diabetes.
Misdiagnosis of Latent Autoimmune Diabetes of Adulthood
Despite adhering to lifestyle modifications, a woman’s glycemic control remains inadequate.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Diabetes
